BioAlliance Pharma Establishes Sales and Marketing Subsidiary to Prepare for Loramyc Launch
Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations. Laboratoires BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc(R), for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005. The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupr?, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.
Paris, May 3, 2006– BioAlliance Pharma SA (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that its new, wholly owned sales and marketing subsidiary, Laboratoires BioAlliance Pharma SAS, has begun formal operations.
Laboratories BioAlliance Pharma will be responsible for all BioAlliance sales and marketing activities, initially focused on the launch of the company's first product Loramyc,® for treatment of oropharyngeal candidiasis, an oral fungus found in association with immune compromised patients. Following regulatory approval expected in late 2006, the product will be launched first in France, followed by additional launches in other selected European countries as approvals are obtained under the mutual recognition procedure. The company filed for Loramyc marketing authorization approval (MAA) in September 2005.
The new subsidiary will be headed by BioAlliance Pharma CEO, Dominique Costantini, MD. Florence Dupre, vice president of sales and marketing and Alain Maquin, Head Pharmacist are the other directors.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
